Home » Sinovac Begins Phase 3 COVID-19 Vaccine Trial in Indonesia
Sinovac Begins Phase 3 COVID-19 Vaccine Trial in Indonesia
Chinese drugmaker Sinovac has begun a phase 3 trial of its COVID-19 vaccine CoronaVac in Indonesia in partnership with state-owned Indonesian drugmaker Bio Farma.
CoronaVac uses an inactivated form of the coronavirus to prompt an immune response. In a phase 2 trial, it induced neutralizing antibodies in 90 percent of participants.
The only local vaccine manufacturer in Indonesia, Bio Farma expects to begin commercial production in six months. CoronaVac is also in phase 3 testing in Brazil.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May